$CORT
Corcept Therapeutics Inc

2020 Q2 Form 10-Q Financial Statement

#000162828020011656 Filed on August 04, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $88.57M $72.26M
YoY Change 22.57% 15.96%
Cost Of Revenue $1.234M $1.377M
YoY Change -10.38% 19.32%
Gross Profit $87.33M $70.88M
YoY Change 23.21% 15.9%
Gross Profit Margin 98.61% 98.09%
Selling, General & Admin $25.57M $24.59M
YoY Change 3.99% 23.07%
% of Gross Profit 29.28% 34.69%
Research & Development $26.50M $21.66M
YoY Change 22.35% 5.42%
% of Gross Profit 30.34% 30.55%
Depreciation & Amortization $200.0K $200.0K
YoY Change 0.0% 100.0%
% of Gross Profit 0.23% 0.28%
Operating Expenses $52.07M $46.25M
YoY Change 12.59% 14.12%
Operating Profit $35.26M $24.63M
YoY Change 43.15% 19.38%
Interest Expense $1.010M $1.180M
YoY Change -14.41% 110.71%
% of Operating Profit 2.86% 4.79%
Other Income/Expense, Net $1.010M $1.178M
YoY Change -14.26% 109.61%
Pretax Income $36.27M $25.81M
YoY Change 40.53% 21.77%
Income Tax $7.900M $5.600M
% Of Pretax Income 21.78% 21.7%
Net Earnings $28.33M $20.19M
YoY Change 40.33% 10.94%
Net Earnings / Revenue 31.98% 27.94%
Basic Earnings Per Share $0.25 $0.18
Diluted Earnings Per Share $0.23 $0.17
COMMON SHARES
Basic Shares Outstanding 115.0M shares 114.3M shares
Diluted Shares Outstanding 123.2M shares 121.8M shares

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $405.4M $201.5M
YoY Change 101.19% 26.02%
Cash & Equivalents $58.52M $58.14M
Short-Term Investments $346.8M $143.4M
Other Short-Term Assets $5.300M $6.200M
YoY Change -14.52% 72.22%
Inventory $4.927M $5.142M
Prepaid Expenses
Receivables $22.73M $19.77M
Other Receivables $0.00 $0.00
Total Short-Term Assets $438.3M $232.7M
YoY Change 88.4% 17.99%
LONG-TERM ASSETS
Property, Plant & Equipment $619.0K $1.177M
YoY Change -47.41% 113.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $4.200M $24.20M
YoY Change -82.64%
Other Assets $4.536M $150.0K
YoY Change 2924.0% -99.8%
Total Long-Term Assets $59.49M $96.02M
YoY Change -38.05% 24.37%
TOTAL ASSETS
Total Short-Term Assets $438.3M $232.7M
Total Long-Term Assets $59.49M $96.02M
Total Assets $497.8M $328.7M
YoY Change 51.46% 19.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.304M $7.026M
YoY Change -10.28% 10.38%
Accrued Expenses $22.63M $16.44M
YoY Change 37.68% -13.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $42.24M $30.38M
YoY Change 39.04% -1.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.900M $200.0K
YoY Change 850.0%
Total Long-Term Liabilities $1.900M $200.0K
YoY Change 850.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $42.24M $30.38M
Total Long-Term Liabilities $1.900M $200.0K
Total Liabilities $44.13M $30.63M
YoY Change 44.08% -0.89%
SHAREHOLDERS EQUITY
Retained Earnings $34.84M -$79.28M
YoY Change -143.94% -49.66%
Common Stock $481.8M $436.7M
YoY Change 10.33% 8.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $453.7M $298.1M
YoY Change
Total Liabilities & Shareholders Equity $497.8M $328.7M
YoY Change 51.46% 19.79%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income $28.33M $20.19M
YoY Change 40.33% 10.94%
Depreciation, Depletion And Amortization $200.0K $200.0K
YoY Change 0.0% 100.0%
Cash From Operating Activities $53.20M $25.50M
YoY Change 108.63% 67.76%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K -$400.0K
YoY Change -75.0%
Acquisitions
YoY Change
Other Investing Activities -$85.90M -$800.0K
YoY Change 10637.5% -96.23%
Cash From Investing Activities -$85.90M -$1.100M
YoY Change 7709.09% -94.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.800M -15.90M
YoY Change -142.77% -487.8%
NET CHANGE
Cash From Operating Activities 53.20M 25.50M
Cash From Investing Activities -85.90M -1.100M
Cash From Financing Activities 6.800M -15.90M
Net Change In Cash -25.90M 8.500M
YoY Change -404.71% -547.37%
FREE CASH FLOW
Cash From Operating Activities $53.20M $25.50M
Capital Expenditures -$100.0K -$400.0K
Free Cash Flow $53.30M $25.90M
YoY Change 105.79% 70.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Entity Central Index Key
EntityCentralIndexKey
0001088856
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2020Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-50679
dei Entity Registrant Name
EntityRegistrantName
CORCEPT THERAPEUTICS INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0487658
dei Entity Address Address Line1
EntityAddressAddressLine1
149 Commonwealth Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Menlo Park
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94025
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
327-3270
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
CORT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
115557656 shares
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58523000 USD
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31269000 USD
CY2020Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
346835000 USD
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
244693000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
22725000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19928000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
4927000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
5424000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5323000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6044000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
438333000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
307358000 USD
CY2020Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
11193000 USD
CY2019Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
11981000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3472000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3446000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
619000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1050000 USD
CY2020Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
4200000 USD
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
39352000 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4536000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3448000 USD
CY2020Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
35470000 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
45677000 USD
CY2020Q2 us-gaap Assets
Assets
497823000 USD
CY2019Q4 us-gaap Assets
Assets
412312000 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6304000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7537000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
181812000 USD
CY2020Q2 cort Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
11289000 USD
CY2019Q4 cort Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
6477000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22631000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23269000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2019000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1558000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
42243000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38841000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1486000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1903000 USD
CY2020Q2 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
396000 USD
CY2019Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
386000 USD
CY2020Q2 us-gaap Liabilities
Liabilities
44125000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
41130000 USD
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
121000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
120000 USD
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
481714000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
457060000 USD
CY2020Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
63814000 USD
CY2019Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
62704000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
840000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
261000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
34837000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23555000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
453698000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
371182000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
497823000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
412312000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
88565000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
72257000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52620000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52620000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41900000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
181812000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
137086000 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1234000 USD
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1377000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3112000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3112000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2617000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26497000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21656000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
25572000 USD
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24591000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
53107000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
53107000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
48980000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
53303000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
47624000 USD
us-gaap Costs And Expenses
CostsAndExpenses
108839000 USD
us-gaap Costs And Expenses
CostsAndExpenses
93497000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
35262000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
24633000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
72973000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
43589000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1010000 USD
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1178000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2481000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2481000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2275000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
36272000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
25811000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
75454000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
45864000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7945000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5625000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17062000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17062000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7404000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
28327000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
20186000 USD
us-gaap Net Income Loss
NetIncomeLoss
58392000 USD
us-gaap Net Income Loss
NetIncomeLoss
38460000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-170000 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-73000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-190000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-124000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
545000 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
227000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
606000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
391000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-27000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
28857000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
20413000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
58971000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
38851000 USD
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.25
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.34
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.23
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115006000 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114340000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114790000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114590000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
123234000 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
121783000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122756000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122831000 shares
us-gaap Profit Loss
ProfitLoss
58392000 USD
us-gaap Profit Loss
ProfitLoss
38460000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
16407000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
14432000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
10017000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
5834000 USD
us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
72000 USD
us-gaap Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
1053000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
362000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
263000 USD
cort Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
749000 USD
cort Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
772000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-148000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2797000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2186000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1414000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1543000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-721000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1538000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1088000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
100000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1251000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1299000 USD
cort Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
4812000 USD
cort Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
2197000 USD
cort Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-730000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
86455000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
49236000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
667000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
89000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-628000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-7349000 USD
cort Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-731000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
153193000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
130145000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
219314000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
131001000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-66210000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1523000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
7347000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3947000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
275000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31269000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41625000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58523000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
30975000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
63000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4169000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7009000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-31197000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
27254000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16516000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58141000 USD
cort Shares Repurchased In Net Settlement Of Cashless Option Exercise
SharesRepurchasedInNetSettlementOfCashlessOptionExercise
772000000 USD
cort Shares Repurchased In Net Settlement Of Cashless Option Exercise
SharesRepurchasedInNetSettlementOfCashlessOptionExercise
931000 USD
cort Non Cash Transaction Recognition Of Right Of Use Asset And Lease Liability
NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability
775000000 USD
cort Non Cash Transaction Recognition Of Right Of Use Asset And Lease Liability
NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability
1878000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
275882000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3366000 USD
CY2019Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
5100000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6724000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
164000 USD
CY2019Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
13555000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
18274000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
285755000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1514000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7791000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
227000 USD
CY2019Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
17420000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
20186000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
298053000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
371182000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
480000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7988000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
49000 USD
CY2020Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
275000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
30065000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
409489000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7639000 USD
CY2020Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
835000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8548000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
530000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
28327000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
453698000 USD
cort Number Of Series Of Selective Cortisol Modulators
NumberOfSeriesOfSelectiveCortisolModulators
4 series
CY2020Q2 cort Inventory Current Noncurrent
InventoryCurrentNoncurrent
16120000 USD
CY2019Q4 cort Inventory Current Noncurrent
InventoryCurrentNoncurrent
17405000 USD
CY2020Q2 cort Inventory Raw Materials Current And Noncurrent
InventoryRawMaterialsCurrentAndNoncurrent
0 USD
CY2019Q4 cort Inventory Raw Materials Current And Noncurrent
InventoryRawMaterialsCurrentAndNoncurrent
1389000 USD
CY2020Q2 cort Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
9413000 USD
CY2019Q4 cort Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
10086000 USD
CY2020Q2 cort Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
6707000 USD
CY2019Q4 cort Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
5930000 USD
CY2020Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
11193000 USD
CY2019Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
11981000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
4927000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
5424000 USD
CY2020Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
2309000 USD
CY2019Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
2378000 USD
CY2020Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
1690000 USD
CY2019Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
1328000 USD
CY2020Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
619000 USD
CY2019Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1050000 USD
CY2020Q2 cort Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
9160000 USD
CY2019Q4 cort Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
8209000 USD
CY2020Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
5615000 USD
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
12331000 USD
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5417000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
472000 USD
CY2020Q2 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
918000 USD
CY2019Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1087000 USD
CY2020Q2 cort Accrued Legal Fees Current
AccruedLegalFeesCurrent
664000 USD
CY2019Q4 cort Accrued Legal Fees Current
AccruedLegalFeesCurrent
491000 USD
CY2020Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
1200000 USD
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
463000 USD
cort Marketable Securities Maximum Maturity Period
MarketableSecuritiesMaximumMaturityPeriod
P2Y
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
367000 USD
CY2020Q2 cort Accrued Manufacturing Costs
AccruedManufacturingCosts
113000 USD
CY2019Q4 cort Accrued Manufacturing Costs
AccruedManufacturingCosts
33000 USD
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
281000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
279000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22631000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23269000 USD
CY2020Q2 cort Deposits For Clinical Trials
DepositsForClinicalTrials
4400000 USD
CY2019Q4 cort Deposits For Clinical Trials
DepositsForClinicalTrials
3300000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
385793000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
302506000 USD
CY2019Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
1000000.0 USD
cort Marketable Securities Weighted Average Maturity Period
MarketableSecuritiesWeightedAverageMaturityPeriod
P6M
cort Long Term Marketable Securities Remaining Maturity
LongTermMarketableSecuritiesRemainingMaturity
P13M
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
800000 USD
cort Number Of Stock Option Plans
NumberOfStockOptionPlans
2 stock_option_plan
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
422000 USD
CY2019Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
391000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
812000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
769000 USD
CY2020Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
775000 USD
CY2019Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P21M
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
4.8
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1055000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2109000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
530000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3694000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
189000 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3505000 USD
CY2020Q1 cort Short Term Purchase Commitment Minimum Mass Required
ShortTermPurchaseCommitmentMinimumMassRequired
400 kg
CY2020Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0 USD
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0 USD
CY2020Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1000000.0 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1100000 shares
CY2019Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
300000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1800000 shares
CY2020Q2 cort Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Net Share Settlement Of Cashless Exercise
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetShareSettlementOfCashlessExercise
100000 shares
cort Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Net Share Settlement Of Cashless Exercise
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodNetShareSettlementOfCashlessExercise
100000 shares
CY2020Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
59000 USD
CY2019Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
55000 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
129000 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
83000 USD
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
8548000 USD
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
7791000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
16536000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
14515000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
28327000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
20186000 USD
us-gaap Net Income Loss
NetIncomeLoss
58392000 USD
us-gaap Net Income Loss
NetIncomeLoss
38460000 USD
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115006000 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114340000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114790000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114590000 shares
CY2020Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
8228000 shares
CY2019Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
7443000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
7966000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
8241000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
123234000 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
121783000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122756000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122831000 shares
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.25
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.34
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.23
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
26400000 shares
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
24700000 shares
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7900000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17100000 USD
CY2020Q2 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
1000000.0 USD
us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
1100000 USD
CY2020Q2 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-4900000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-10000000.0 USD
CY2020Q2 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
3000000.0 USD
us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
7000000.0 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5600000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7400000 USD
CY2019Q2 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-4900000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-5800000 USD
CY2019Q2 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
700000 USD
us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
1600000 USD

Files In Submission

Name View Source Status
0001628280-20-011656-index-headers.html Edgar Link pending
0001628280-20-011656-index.html Edgar Link pending
0001628280-20-011656.txt Edgar Link pending
0001628280-20-011656-xbrl.zip Edgar Link pending
cort-20200630.htm Edgar Link pending
cort-20200630.xsd Edgar Link pending
cort-20200630_cal.xml Edgar Link unprocessable
cort-20200630_def.xml Edgar Link unprocessable
cort-20200630_htm.xml Edgar Link completed
cort-20200630_lab.xml Edgar Link unprocessable
cort-20200630_pre.xml Edgar Link unprocessable
cort63020ex311.htm Edgar Link pending
cort63020ex312.htm Edgar Link pending
cort63020ex321.htm Edgar Link pending
cort63020ex322.htm Edgar Link pending
cortex101severanceandc.htm Edgar Link pending
cortex102severanceandc.htm Edgar Link pending
cortex103severanceandc.htm Edgar Link pending
cortex104fifthamendmen.htm Edgar Link pending
exhibitafourthexpansio1.jpg Edgar Link pending
exhibitbpremises11.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending